Last reviewed · How we verify

Clostridium difficile diarrhea — Treatment Landscape & Competitive Intelligence

Clostridium difficile diarrhea (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Clostridium difficile diarrhea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vancocin vancomycin ANI Pharmaceuticals Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. ANI Pharmaceuticals · 1 drug in Clostridium difficile diarrhea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Clostridium difficile diarrhea:

Cite this brief

Drug Landscape (2026). Clostridium difficile diarrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/clostridium-difficile-diarrhea. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing